Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.54 |
| ▸ | ABL1 | P00519 | 13/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377132 | 0.88 | KIF11 (0.54) | KIF11ABL1CYP17A1SCN9A | |
| SCHEMBL3378380 | 0.87 | KIF11 (0.53) | KIF11ABL1CYP17A1SLC22A12 | |
| SCHEMBL3377794 | 0.87 | DHODH (0.56) | KIF11ABL1CYP17A1SLC22A12 | |
| SCHEMBL3375773 | 0.86 | KIF11 (0.70) | KIF11ABL1CYP17A1BCR | |
| SCHEMBL3378867 | 0.86 | KIF11 (0.52) | KIF11ABL1CYP17A1 | |
| SCHEMBL3375676 | 0.83 | KIF11 (0.52) | KIF11ABL1CYP17A1SLC22A12 | |
| SCHEMBL3379953 | 0.83 | KIF11 (0.74) | KIF11ABL1BCR | |
| SCHEMBL28058379 | 0.81 | KIF11 (0.60) | KIF11ABL1SLC22A12 | |
| SCHEMBL3375898 | 0.81 | KIF11 (0.58) | KIF11SCN9A | |
| SCHEMBL13369737 | 0.79 | CYP17A1 (0.54) | KIF11CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | KIF11 3561/4885ABL1 1571/4885CYP17A1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.